EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.60, no.5, pp.337-342, 2004 (SCI-Expanded)
Objective. Cytochrome P-450 2C9 (CYP2C9) is a polymorphic enzyme catalysing the metabolism of several important drugs. Losartan has recently been suggested as a selective probe for CYP2C9 metabolic activity. The aim of the study was to determine the activity of CYP2C9, using losartan as a probe drug, in relation to CYP2C9 genotype in healthy Turkish subjects.